Julio E. Vega

Julio also has experience advising on international transactions and is fluent in Spanish.

Prior to joining Morgan Lewis, Julio was a partner in the emerging company, venture capital, mergers and acquisitions and securities practice of another international firm.

M&A Transactions

• enGene, Inc. as U.S. counsel in its definitive business combination with Forbion European Acquisition Corp.
• 128 Technology, an AI driven software-defined wide area networks provider, in its $450 million sale to Juniper Networks
• Rhythm Health, Inc. in connection with its grant to Actavis of an option to acquire Rhythm Health
• Sideris Pharmaceuticals in connection with its grant to Novartis of an option to acquire Sideris
• Proteon Therapeutics in connection with its grant to Novartis of an option to acquire Proteon
• Bioassets Development Corp. in connection with its sale to Cephalon
• VisEn Medical in connection with its acquisition by PerkinElmer
• Novazyme Pharmaceuticals in connection with its acquisition by Genzyme
• Cubist Pharmaceuticals in connection with its acquisition of Calixa
• LeukoSite in connection with its acquisition by Millennium Pharmaceuticals
• Acme Packet in connection with its acquisitions of Covergence
• Acme Packet in connection with its acquisitions of Newfound Communications
• Acme Packet in connection with its acquisitions of Iptego GmbH
• Acme Packet in connection with its sale to Oracle
• E Ink in connection with its sale to PrimeView International
• Voice Signal Technologies in connection with its acquisition by Nuance Communications

Licensing and Collaboration Transactions

• Biogen Idec in connection with Option and License Agreement with AVEO Pharmaceuticals
• Radius Health Inc. in connection with License Agreement with Ipsen S.A.
• BioAssets Development Corporation in connection with Collaboration and License Agreement between BioAssets and Biogen Idec (via Eidetica Biopharma GmbH)
• Serono S.A. in connection with Research Collaboration and License Agreement with Paratek Pharmaceuticals
• Serono S.A. in connection with Research Collaboration and License Agreement with Ambrx Pharmaceuticals
• Fovea Pharmaceuticals, S.A. in connection with License Agreement with Dyax Corp.
• Proteostasis Therapeutics in connection with Strategic Alliance Agreement with Elan
• Rhythm Pharmaceuticals in connection with in-license from Ipsen S.A.
• TolerRx in connection with License Agreement with GlaxoSmithKline plc

IPOs

• Initial Public Offering of Proteon Therapeutics (issuer’s counsel)
• Initial Public Offering of Radius Health (underwriter’s counsel)
• Initial Public Offering of Rhythm Pharmaceuticals, Inc. (issuer’s counsel)
• Initial Public Offering of Amicus Therapeutics, Inc. (issuer’s counsel)
• Initial Public Offering of Acme Packet, Inc. (issuer’s counsel)
• Initial Public Offering of Aspen Technology, Inc. (issuer’s counsel)
• Initial Public Offering of Cubist Pharmaceuticals, Inc. (issuer’s counsel)
• Initial Public Offering of Leukosite, Inc. (issuer’s counsel)
• Initial Public Offering of Acme Packet, Inc. (issuer’s counsel)

Venture Financings

• QurAlis Corporation in its $88 million Series B financing
• Strand Therapeutics in its $40 million Series A-2 financing
• Bellevue Capital in the $132 million Series B financing of Rivus Pharmaceuticals Inc.